Agreement with ICAD and clinical partner Panegreen to assess adding Portuguese sites to the alcohol addiction trial.
Solvonis Therapeutics plc has signed a memorandum of understanding (MoU) with ICAD (Instituto para os Comportamentos Aditivos e as Dependências, I.P.), Portugal’s public addiction institute, attached to Portugal’s Ministry of Health, and Panegreen – Health & Wellness Solutions, Lda., which operates The Clinic of Change, a ketamine-assisted psychotherapy clinic in Lisbon.
The MoU is to assess adding Portuguese trial sites to MORE-KARE, the UK Phase 3 trial of SVN-001 for severe alcohol use disorder. MORE-KARE is sponsored by the University of Exeter and co-funded by Solvonis, the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC). Solvonis will take the proposal to the University of Exeter, NIHR and MRC.
The MoU has an initial six-month term and does not create a binding commitment to proceed with Portuguese trial participation. Any participation remains subject to sponsor and funder agreement and the required ethics, regulatory, contractual, funding and governance approvals.
Released through a Regulatory Information Service on 13 October 2026. View the RNS